Atossa Genetics currently holds roughly 125.54
M in cash with (16.47
M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Investing in Atossa Genetics, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Atossa Genetics along with other instruments in the same portfolio. Using conventional
technical analysis and
fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Watch out for price decline
Please consider monitoring Atossa Genetics on a daily basis if you are holding a position in it. Atossa Genetics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Atossa Genetics stock to be traded above the $1 level to remain listed. If Atossa Genetics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Atossa Genetics's Liquidity
Atossa Genetics
financial leverage refers to using borrowed capital as a funding source to finance Atossa Genetics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Atossa Genetics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Atossa Genetics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Atossa Genetics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Atossa Genetics's total debt and its cash.
Atossa Genetics Gross Profit
Atossa Genetics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Atossa Genetics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Atossa Genetics Gross Profit growth over the last 10 years. Please check Atossa Genetics'
gross profit and other
fundamental indicators for more details.
Atossa Genetics Correlation with Peers
Investors in Atossa can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Atossa Genetics. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Atossa Genetics and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Atossa is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with
your current brokerage. Please check
volatility of Atossa for more details
A Deeper look at Atossa
We consider Atossa Genetics dangerous.
Atossa Genetics secures Sharpe Ratio (or Efficiency) of 0.0266, which signifies that the company had 0.0266% of return per unit of risk over the last 3 months. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock-specific
technical indicators that cannot be
diversified away. We have found twenty-seven
technical indicators for Atossa Genetics, which you can use to evaluate the future volatility of the firm. Please confirm Atossa Genetics Mean Deviation of 3.54,
risk adjusted performance of 0.0102, and Downside Deviation of 4.09 to double-check if the risk estimate we provide is consistent with the expected return of 0.13%.
Atossa Genetics has 54 percent chance to drop under USD0.73 in the coming weeks
Atossa Genetics information ratio is up to 0.01. Atossa Genetics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Atossa Genetics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Atossa Genetics future alpha. Atossa Genetics is a potential penny stock. Although Atossa Genetics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Atossa Genetics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Atossa instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.
Our Conclusion on Atossa Genetics
Whereas many of the other players in the biotechnology industry are either recovering or due for a correction, Atossa Genetics may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the newest economy, it is better to hold off any trading of Atossa as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Atossa Genetics.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Aina Ster is a Member of Macroaxis Editorial Board. Aina delivers weekly perspective on ongoing market and economic trends, analysis and tips from predictive analysis to forecasting across various financial instruments.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Aina Ster do not own shares of Atossa Genetics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
